Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

15.18 -0.38 (-2.44%)

Streaming Delayed Price Updated: 10:50 AM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

35 36 Next >

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 31, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

March 31, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price...

Via StockStory

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

8 Analysts Have This To Say About Sarepta Therapeutics ↗

February 27, 2025

Via Benzinga

Earnings Scheduled For February 26, 2025 ↗

February 26, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 26, 2025

From Pomerantz LLP

Via GlobeNewswire

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Is This Stock a Buy After a Massive 20% Drop in 1 Day? ↗

March 23, 2025

Via The Motley Fool

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up ↗

March 21, 2025

Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.

Via Stocktwits

Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

March 18, 2025

U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31

Via Benzinga

Topics Economy Stocks

12 Analysts Have This To Say About Sarepta Therapeutics ↗

March 18, 2025

Via Benzinga

Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday? ↗

March 18, 2025

Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York.

Via Benzinga

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge ↗

March 18, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 18, 2025

Via Benzinga

Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today

March 18, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with...

Via StockStory

Discover the top movers in Tuesday's pre-market session. ↗

March 18, 2025

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Via Chartmill

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges ↗

March 18, 2025

Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.

Via Benzinga

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies ↗

March 18, 2025

The patient also had a recent CMV infection, which the company said could have contributed.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 18, 2025

Via Benzinga

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases ↗

March 10, 2025

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.

Via Benzinga

SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectations ↗

March 04, 2025

A fundamental analysis of (NASDAQ:SRPT): SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) may be suited for growth investing, we'll explore why in this article.

Via Chartmill

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

March 04, 2025

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.

Via StockStory

Topics Artificial Intelligence

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

February 28, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcript ↗

February 26, 2025

SRPT earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue

February 26, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was...

Via StockStory

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments

February 26, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

February 26, 2025

Via Benzinga

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

February 25, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.

Via StockStory

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

All News about Sarepta Therapeutics, Inc. - Common Stock